Sanofi’s Paul Hud­son pays $357M to buy a biotech part­ner, adding an NK strat­e­gy in the lat­est move to beef up can­cer R&D

A year af­ter Am­s­ter­dam-based Kiadis un­der­went a wrench­ing re­or­ga­ni­za­tion af­ter its lead drug went pffffffft at the EMA, bat­ter­ing the share price and butcher­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER